Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, June 22, 2026

New trigger for Alzheimer's disease may have been found

 Have your competent? doctor analyze these other possibilities AND DELIVER EXACT PREVENTION PROTOCOLS! Can't do that, you don't have a functioning stroke doctor!

 January 2024

New trigger for Alzheimer's disease may have been found

A new study is raising questions about one of the most widely held ideas in Alzheimer’s research—suggesting the disease may not start with plaques in the brain after all. 

Researchers at the University of California, Riverside (UCR) say the earliest changes could instead happen inside nerve cells, where two key proteins appear to interfere with each other. 

For years, much of the focus has been on amyloid beta, or a-beta, because it forms clumps in the brains of people with Alzheimer’s. That link appeared well supported, especially since genetic mutations that increase a-beta levels are known to cause early-onset forms of the disease. 

But attempts to treat Alzheimer’s by removing these clumps have been largely unsuccessful, with thousands of trials failing to stop or reverse its progression. 

Michael Kane, chief medical officer at Indiana Center for Recovery, told Newsweek that the findings of this study should not be seen as dismissing the amyloid theory entirely, but rather as refining it.

“I see these findings less as a rejection of the amyloid theory and more as a possible link between amyloid beta and tau,” he said. 

Connection Between Amyloid Beta and Tau 

Scientists have long known that another protein, tau, is also involved. Both a-beta and tau build up in the brains of people diagnosed with Alzheimer’s, yet how they are connected has remained unclear. 

“In addition to having dementia, Alzheimer’s diagnosis requires both a-beta and tau buildup in the brain,” said study lead author Ryan Julian, a chemistry professor at UCR. “But many labs focus on the role of one and ignore the other.” 

The new study, published in Proceedings of the National Academy of Sciences, Nexus, looks at what happens when the two proteins are present inside the same cell. 

Kane said this connection is one of the most significant aspects of the research.

“Amyloid beta and tau have both been central to Alzheimer’s research for decades, but the field has struggled to explain exactly how they interact. This study gives scientists a more specific place to look,” he said.   

What Happens Inside Nerve Cell 

Tau normally supports structures called microtubules, which act as internal pathways, helping nerve cells move essential materials to where they are needed. 

The researchers found that the part of tau that attaches to these structures is very similar to amyloid beta. That similarity led them to examine whether a-beta could attach to microtubules in the same way. 

Using a fluorescent marker to track the protein, the team observed that a-beta can bind to microtubules with similar strength to tau. 

“Our work shows amyloid beta and tau compete for the same binding sites on microtubules, and that a-beta can prevent tau from functioning correctly,” Julian said. 

Kane said this mechanism could represent an earlier stage of disease development than previously recognised.

“The damage may start earlier, with the cell’s machinery becoming less stable,” he said.   

Disruption That May Come First 

The researchers suggest that this competition could be an important early step. 

If a-beta builds up inside a neuron, it may push tau away from the microtubules. Without tau in place, the cell’s transport system may begin to break down. 

At the same time, tau may start to change behavior—clumping together and moving into areas of the cell where it is not normally found. 

This points to a different way of thinking about the disease. Instead of protein buildup being the starting cause on its own, the two processes may be part of a wider problem inside cells. 

Kane cautioned that while the explanation is biologically plausible, it remains a working model. “A plausible mechanism is not the same as proof that this is what drives Alzheimer’s in patients,” he said.   

Ageing May Play Role 

The study also highlights a process called autophagy, which normally clears unwanted proteins from cells, including a-beta. 

As this process becomes less efficient with age, autophagy may begin to accumulate inside neurons. This could increase the chances of it competing with tau and interfering with normal cell function. 

What It Could Mean Going Forward 

The findings may help explain why some earlier approaches to treatment have struggled to make a difference. 

They also suggest that future research may look more closely at how these proteins interact inside cells, rather than focusing only on removing them once they have formed clumps. 

Julian said the idea helps bring together different strands of research. 

“This idea helps make sense of many results that previously seemed unrelated,” he said. “It gives us a clearer picture of what may be going wrong inside neurons and where new treatments might start.” 

Kane said the study could point scientists toward new types of therapeutic strategies, but warned against overstating its immediacy.

“It could point researchers toward targets inside the neuron, such as protecting microtubules or preventing amyloid beta from interfering with tau—but I would not describe it as an immediate treatment breakthrough,” he said.  

He added that the most important next step is confirming whether the process occurs in people.

“Researchers need to know when it happens, who it happens in, and whether it tracks with memory loss or functional decline over time,” he said.  

Kane also urged caution in interpreting the findings.

“The most useful part of this study is that it moves the conversation from what we see after neurons are already damaged to what may be going wrong inside the neuron earlier,” he said. “That is where better treatments may eventually come from.” 

Related Articles

Start your unlimited Newsweek trial

No comments:

Post a Comment